Loading…
← CockpitCompetitor Analysis › PRAX Praxis Precision Medicines, Inc.Open in the cockpit ↗

Praxis Precision Medicines, Inc.PRAXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech developing central-nervous-system drugs for epilepsy and essential tremor, with its first products nearing approval.

Momentum neutral 48
Mkt cap
$8.53B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$143M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-81.8 pp
WACC 19.4%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$305.19
1D0.0%
1W-11.8%
1M+15.4%
3M-16.3%
6M-9.1%
YTD+3.5%
1Y+54.5%
ATR %6.0%
Beta1.57
52w lowhigh22.3% off high

What Praxis Precision Medicines does

Biotech developing central-nervous-system drugs for epilepsy and essential tremor, with its first products nearing approval.

Has so far depended on money raised from investors rather than product sales to pay for trials, so trial results and fundraising matter more than sales. Its drugs act on ion channels, the pores that control nerve-cell firing, and it targets groups of patients defined by a specific genetic cause. Future income would come from selling approved drugs or licensing them.

Products and services

  • Ulixacaltamide (essential tremor, pipeline)
  • Epilepsy pipeline (relutrigine and others)

Customers

  • Neurologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • CNS - epilepsy, movement disorders

What could go right

  • Potential first approvals in essential tremor/epilepsy
  • Large underserved CNS patient populations

What could go wrong

  • Pre-revenue clinical and regulatory risk
  • Cash burn ahead of commercial launch

Moat: narrow (IP / patents, process know-how). Proprietary ion-channel drug-discovery platform targeting genetically defined CNS disorders.

Headquarters: Boston, Massachusetts, United States · Founded: 2015 · Employees: 168

Named competitors

Praxis Precision Medicines at a glance

Size Praxis Precision Medicines (PRAX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $8.53B, the 855th largest of 3,085 United States companies the cockpit tracks. Shares closed at $305.19 on 18 Nov 2026.

Performance Over six months the shares fell 9.1%, against +19.2% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue fell 100.0% over the last twelve months (peer median +16.2%).

Capital Return on invested capital runs 81.8 points below its cost of capital (19.4% WACC).

Short interest Short interest is 15.1% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 118PRAX 87
Six months, rebased to 100: Praxis Precision Medicines against the median of its 20 peers (local-currency closes).

Praxis Precision Medicines financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$8.55M$2.45M$0
Revenue growth—-100%+250%——
Gross profit-$133,000-$140,000$8.20M$2.02M-$1.17M
EBITDA-$407M-$326M-$200M-$126M-$214M
Net income-$359M-$303M-$183M-$123M-$214M
Free cash flow-$324M-$249M-$132M-$110M-$185M
Capital expenditure$5.86M$56,000$0$50,000$444,000
Total debt$732,000$110,000$1.37M$2.50M$3.50M

Quarterly statements and history in the cockpit →

Praxis Precision Medicines competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%4151PTGX2607RYTMGLENMARKHLUN-AALK-BALKSMDGL2196AMRXSYRE3759GRFKNSACORTTGTX002821CYTKPRAX6-month return →1-month return →
Up and to the right = strong over both horizons. Praxis Precision Medicines is the large dot.

Praxis Precision Medicines competitors and peer comparison

Head to head with its named competitors (PRAX vs JAZZ vs XENE vs NBIX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Praxis Precision Medicines PRAX$8.53B-9%-100%n/an/an/a
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%4.0×-2.8%
Xenon Pharmaceuticals XENE$3.71B-31%-100%n/an/an/a
Neurocrine Biosciences NBIX$16.5B+5%+38%25%4.4×-1.5%
Supernus Pharmaceuticals SUPN$6.02B-41%+16%45%4.5×6.2%

How Praxis Precision Medicines compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Praxis Precision Medicines against its 20 peers (data as of 18 Nov 2026)
MeasurePRAXPeer medianRank in peer set
1-month return+15.4%+4.2%5th highest of 21
6-month return-9.1%+19.2%4th lowest of 21
Distance from 52-week high-22.3%-10.8%7th lowest of 21
Revenue growth (TTM)-100.0%+16.2%lowest of 20
ROIC minus cost of capital-81.8 pp+4.3 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%2.1×-4.7%+9.3%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%13.6×17.5%+10.0%
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%0.3×-9.7%+7.4%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%29.0×n/an/a
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%4.7×27.3%+9.4%
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%2.6×-6.6%+6.6%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%7.4×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%5.0×32.5%+7.3%
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%6.0×n/an/a
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%2.2×19.9%+5.8%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%3.4×17.2%+8.7%
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Pharmaron Beijing 3759.HKHong Kong$9.65B+48%+24%14%4.4×n/an/a
Grifols GRF.MCSpain$7.48B+19%+1%16%2.4×7.1%+7.1%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%7.3×10.4%+45.5%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%7.3×23.9%+16.6%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%2.1×-6.8%+10.8%
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%11.4×43.0%+426.7%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%5.7×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%64.3×n/an/a

Questions

Who are Praxis Precision Medicines's main competitors?
Named competitors: UCB (private or unlisted), SK Life Science (private or unlisted), Jazz Pharmaceuticals (JAZZ), Xenon Pharmaceuticals (XENE), Neurocrine Biosciences (NBIX), Supernus Pharmaceuticals (SUPN). The cockpit's measured peer set (industry) also includes Kyowa Kirin (4151.T), Protagonist Therapeutics (PTGX), Shanghai Pharmaceuticals (2607.HK), Rhythm Pharmaceuticals (RYTM), Glenmark Pharmaceuticals (GLENMARK.NS), H. Lundbeck A/S (HLUN-A.CO).
How has Praxis Precision Medicines stock performed?
Over six months to 18 Nov 2026 the shares returned -9.1% against +19.2% for the median peer; over one year +54.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.